BNP Paribas Financial Markets Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

BNP Paribas Financial Markets increased its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 2,166.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,197 shares of the company’s stock after purchasing an additional 25,997 shares during the quarter. BNP Paribas Financial Markets owned 0.06% of Kyverna Therapeutics worth $133,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC purchased a new stake in Kyverna Therapeutics in the third quarter worth approximately $33,000. Teachers Retirement System of The State of Kentucky grew its stake in shares of Kyverna Therapeutics by 69.7% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 21,410 shares of the company’s stock valued at $161,000 after purchasing an additional 8,796 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Kyverna Therapeutics by 32.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company’s stock worth $283,000 after purchasing an additional 9,300 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Kyverna Therapeutics by 55.8% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company’s stock worth $196,000 after buying an additional 9,385 shares during the last quarter. Finally, Creative Planning bought a new stake in Kyverna Therapeutics during the third quarter valued at approximately $54,000. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Trading Down 9.5 %

Kyverna Therapeutics stock opened at $3.79 on Thursday. The firm’s 50 day moving average price is $4.97 and its 200-day moving average price is $6.98. Kyverna Therapeutics, Inc. has a 1 year low of $3.77 and a 1 year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.01. The company had revenue of $0.01 million for the quarter. On average, equities analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on KYTX. HC Wainwright dropped their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. UBS Group assumed coverage on shares of Kyverna Therapeutics in a report on Thursday, October 10th. They issued a “buy” rating and a $13.00 target price for the company. Rodman & Renshaw started coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Wells Fargo & Company dropped their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Kyverna Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $25.71.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.